Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jespersen

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Ugeskrift for Laeger|October 19, 1999
[Revascularization in the treatment of ischemic heart disease--state of development in Denmark]M Jespersen
Sygeplejersken|November 4, 1992
[Local wages--on a collision course. Negotiations 93]M Jespersen
Sygeplejersken|June 7, 1989
[Economic policy. Less in available income with plan of social democrats]M Jespersen
Sygeplejersken|January 2, 1992
[Local wages--a risk of breach in agreement]M Jespersen
Sygeplejersken|August 23, 1989
[Economic policy. Greatest burden put on middle and low incomes]M Jespersen
Journal of Cardiovascular Pharmacology|January 1, 1991
The effect of verapamil on major events in patients with exercise-induced ischemia recovering from acute myocardial infarction: a review. The Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Cardiovascular Drugs and Therapy|April 8, 2000
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Journal of Clinical Pharmacology|January 1, 1990
Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Ugeskrift for Laeger|May 21, 1990
[Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris]C M Jespersen
Cardiologia (Rome, Italy)|December 1, 1995
Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?C M Jespersen
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Ugeskrift for Laeger|October 19, 1999
[Revascularization in the treatment of ischemic heart disease--state of development in Denmark]M Jespersen
Sygeplejersken|November 4, 1992
[Local wages--on a collision course. Negotiations 93]M Jespersen
Sygeplejersken|June 7, 1989
[Economic policy. Less in available income with plan of social democrats]M Jespersen
Sygeplejersken|January 2, 1992
[Local wages--a risk of breach in agreement]M Jespersen
Sygeplejersken|August 23, 1989
[Economic policy. Greatest burden put on middle and low incomes]M Jespersen
Journal of Cardiovascular Pharmacology|January 1, 1991
The effect of verapamil on major events in patients with exercise-induced ischemia recovering from acute myocardial infarction: a review. The Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Cardiovascular Drugs and Therapy|April 8, 2000
Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trialsC M Jespersen
European Journal of Clinical Pharmacology|January 1, 1990
Assessment of blindness in the Danish Verapamil Infarction Trial II (DAVIT II). Danish Study Group on Verapamil in Myocardial InfarctionC M Jespersen
Ugeskrift for Laeger|May 21, 1990
[Isoptin Retard. Pharmacokinetics and pharmacodynamics in patients with angina pectoris]C M Jespersen
Cardiologia (Rome, Italy)|December 1, 1995
Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?C M Jespersen
Pageof 12